Company intelligence / Profile preview

Sengi

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Sengi is a pre-clinical stage biotechnology company focused on developing small molecule therapeutics that modulate mitophagy to treat neurodegenerative diseases. Founded by Atlas Venture and based on the pioneering research of Dr. Peter Lansbury, the company targets the selective degradation of damaged mitochondria to restore cellular homeostasis and neuronal health. Sengi's platform leverages deep expertise in mitochondrial biology and protein degradation pathways to identify novel drug candidates for conditions such as Parkinson's disease. The company is currently advancing its discovery-stage programs toward clinical development. Sengi is headquartered in Cambridge, Massachusetts, and is led by a team of experienced industry executives.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sengi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sengi.

Explore the full profile